Sarcomas and pharmacogenetics

Pharmacogenomics

Volumn 6, Issue 6, 2005, Pages 585-601

  Biason, Paola ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Anthracyclines; Cisplatin; ET 743; Imatinib; Methotrexate; Pharmacogenetics; Sarcoma

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CARRIER PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2C9; DACARBAZINE; DACTINOMYCIN; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; EPIRUBICIN; FOLIC ACID; GEMCITABINE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; IFOSFAMIDE; IMATINIB; MESNA; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR; TEMOZOLOMIDE; THYMIDYLATE SYNTHASE; TROFOSFAMIDE; UNINDEXED DRUG; VINCRISTINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DNA REPAIR; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; EDEMA; ENZYME METABOLISM; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; FATIGUE; FREQUENCY ANALYSIS; GASTROINTESTINAL TUMOR; GENE FREQUENCY; GENE MUTATION; GENETIC MARKER; GENETIC POLYMORPHISM; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; METASTASIS POTENTIAL; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; OUTCOMES RESEARCH; PAIN; PHARMACOGENETICS; PHENOTYPE; PREDICTION; PROTEIN FUNCTION; PROTEIN TARGETING; RASH; REVIEW; SARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; VOMITING;

FORECASTING; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PHARMACOGENETICS; SARCOMA;

EID: 25144454121     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.6.585     Document Type: Review

References (104)

1. Demetri GD: ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 13(Suppl. 1), S7-S9 (2002).
2. Antman K, Crowley J, Balcerzak SP et al.: An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 11(7), 1276-1285 (1993).
3. Bramwell VH, Mouridsen HT, Santoro A et al.: Cyclophosphamide versus ifosfamide: final report of a randomized Phase II trial in adult soft tissue sarcomas. Eur. J. Cancer Clin. Oncol. 23(3), 311-321 (1987).
4. Edmonson JH, Ryan LM, Blum RH et al.: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11 (7), 1269-1275 (1993).
5. O'Bryan RM, Baker LH, Gottlieb JE et al.: Dose response evaluation of adriamycin in human neoplasia. Cancer 39(5), 1940-1948 (1977).
6. Yap BS, Baker LH, Sinkovics JG et al.: Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat. Rep. 64(1), 93-98 (1980).
7. Gortzak F, Azzarelli A, Buesa J et al.: A randomised Phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur. J. Cancer 37(9), 1096-1103 (2001).
8. Patel SR, Vadhan-Raj S, Papadopolous N C et al.: High-dose ifosfamide in bone and soft tissue sarcomas: results of Phase II and pilot studies - dose-response and schedule dependence. J. Clin. Oncol. 15(6), 2378-2384 (1997).
9. Provisor AJ, Ettinger LJ, Nachman JB et al.: Treatment of nonmecastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J. Clin. Oncol. 15(1), 76-84 (1997).
10. Zalupski MM, Rankin C, Ryan JR et al.: Adjuvant therapy of osteosarcoma - a Phase II trial: Southwest Oncology Group study 9139. Cancer 100(4), 818-825 (2004).
11. Berrak SG, Pearson M, Berberoglu S, Ilhan IE, Jaffe N: High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr. Blood Cancer 44(3), 215-219 (2005).
12. Van Winkle P, Angiolillo A, Krailo M et al.: Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr. Blood Cancer 44(4), 338-347 (2005).
13. Frustaci S, Gherlinzoni F, De Paoli A et al.: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol. 19(5), 1238-1247 (2001).
14. Garcia-Carbonero R, Supko JG, Manola J et al.: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. 22(8), 1480-1490 (2004).
15. Rankin C, von Mehren M: Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - a Phase III sarcoma group study S0033. Proceedings of the Annual Meeting of Am. Soc. Clin. Oncol. (2004).
16. Verweij J, van Oosterom A, Blay JY et al.: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer 39(14), 2006-2011 (2003).
17. von Mehren M: High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs). Proceedings of the Annual Meeting of Am. Soc. Clin. Oncol. (2002).
18. Guilhot F: Indications for imatinib mesylate therapy and clinical management. Oncologist 9(3), 271-281 (2004).
19. Verweij J, Casali PG, Zalcberg J JY et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440), 1127-1134 (2004).
20. Hall AM, Wilkins MR: Warfarin: a case history in pharmacogenetics. Heart 91(5), 563-564 (2005).
21. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004).
22. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
23. Nagasubramanian R, Innocenti F, Ratain MJ: Pharmacogenetics in cancer treatment. Annu. Rev. Med. 54, 437-452 (2003).
24. Ingelman-Sundberg M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 89-104 (2004).
25. Huang Z, Roy P, Waxman DJ: Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59(8), 961-972 (2000).
26. Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab. Dispos. 27(6), 655-666 (1999).
27. Lang T, Klein K, Fischer J et al.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11(5), 399-415 (2001).
28. Xie HJ, Yasar U, Lundgren S et al.: Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 3(1), 53-61 (2003).
29. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y, Kamataki T: A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun. 281(5), 1256-1260 (2001).
30. Kumar S, Chen CS, Waxman DJ, Halpert JR: Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J. Biol. Chem. 280(20), 19569-19575 (2005).
31. Griskevicius L, Yasar U, Sandberg M et al.: Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur. J. Clin. Pharmacol. 59(2), 103-109 (2003).
32. Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54(10), 1257-1270 (2002).
33. Blaisdell J, Mohrenweiser H, Jackson J et al.: Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12(9), 703-711 (2002).
34. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269(22), 15419-15422 (1994).
35. Ferguson RJ, de Morais SM, Benhamou S et al.: A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284(1), 356-361 (1998).
36. Goldstein JA: Clinical relevance of generic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52(4), 349-355 (2001).
37. Ren S, Yang JS, Kalhorn TF, Slattery JT: Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res. 57(19), 4229-4235 (1997).
38. Eiselt R, Domanski TL, Zibat A et al.: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11(5), 447-458 (2001).
39. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M: Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259(1), 201-205 (1999).
40. Ball SE, Scatina J, Kao J et al.: Population distribution and effects on drug metabolism of a generic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66(3), 288-294 (1999).
41. McCune JS, Risler LJ, Phillips BR et al.: Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab. Dispos. (2005).
42. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 27(4), 383-391 (2001).
43. Rochat B: Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin. Pharmacokinet. 44(4), 349-366 (2005).
44. Dai D, Zeldin DC, Blaisdell JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7), 597-607 (2001).
45. Strange RC, Spiteri MA, Ramachandran S, Fryer AA: Glutathione-S-transferase family of enzymes. Mutat. Res. 482(1-2), 21-26 (2001).
46. Sweeney C, Ambrosone CB, Joseph L et al.: Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int. J. Cancer 103(6), 810-814 (2003).
47. Autrup JL, Hokland P, Pedersen L, Autrup H: Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia. Eur. J. Pharmacol. 438(1-2), 15-18 (2002).
48. Howells RE, Redman CW, Dhar KK et al.: Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin. Cancer Res. 4(10), 2439-2445 (1998).
49. Khedhaier A, Remadi S, Corbex M et al.: Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br. J. Cancer 89(8), 1502-1507 (2003).
50. Ambrosone CB, Sweeney C, Coles BF et al.: Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 61(19), 7130-7135 (2001).
51. Medeiros R, Pereira D, Afonso N et al.: Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int. J. Clin. Oncol. 8(3), 156-161 (2003).
52. Berwick M, Matullo G, Song YS et al.: Association between aryl hydrocarbon receptor genotype and survival in soft tissue sarcoma. J. Clin. Oncol. 22(19), 3997-4001 (2004).
53. Sweeney C, McClure GY, Fares MY et al.: Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. 60(20), 5621-5624 (2000).
54. Yang G, Shu XO, Ruan ZX et al.: Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103(1), 52-58 (2005).
55. Zielinska E, Zubowska M, Bodalski J: Polymorphism at the glutathione S-transferase π locus as a risk factor for ifosfamide nephrotoxicity in children. Pol. Merkuriusz. Lek. 14(82), 295-298 (2003).
56. Komiya S, Gebhardt MC, Mangham DC, Inoue A: Role of glutathione in cisplatin resistance in osteosarcoma cell lines. J. Orthop. Res. 16(1), 15-22 (1998).
57. Gifford AJ, Kavallaris M, Madafiglio J et al.: P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int. J. Cancer 78(2), 176-181 (1998).
58. Imanishi T, Abe Y, Suto R et al.: Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma. Tokai J. Exp. Clin. Med. 19(1-2), 39-46 (1994).
59. Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B: The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 42(9), 496-503 (2004).
60. Kamazawa S, Kigawa J, Kanamori Y et al.: Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol. Oncol. 86(2), 171-176 (2002).
61. Mahon FX, Belloc F, Lagarde V et al.: MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101(6), 2368-2373 (2003).
62. Itoda M, Saito Y, Soyama A et al.: Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab. Dispos. 30(4), 363-364 (2002).
63. Itamochi H, Kigawa J, Sultana H et al.: Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J. Cancer Res. 93(6), 723-728 (2002).
64. Yang R, Sowers R, Mazza B et al.: Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin. Cancer Res. 9(2), 837-844 (2003).
65. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta 1587(2-3), 164-173 (2002).
66. Guo W, Healey JH, Meyers PA et al.: Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res. 5(3), 621-627 (1999).
67. Wolf J, Stranzl T, Filipits M et al.: Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(4), 564-568 (2004).
68. Ifergan I, Meller I, Issakov J, Assaraf YG: Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 98(9), 1958-1966 (2003).
69. Chango A, Emery-Fillon N, de Courcy GP et al.: A polymorphism (80G>A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol. Genet. Metab 70(4), 310-315 (2000).
70. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100(10), 3832-3834 (2002).
71. Serra M, Reverter-Branch, Maurici D et al.: Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann. Oncol. 15(1), 151-160 (2004).
72. Srimatkandada S, Schweitzer BI, Moroson BA, Dube S, Bertino JR: Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J. Biol. Chem. 264(6), 3524-3528 (1989).
73. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20(3), 191-197 (1995).
74. Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW: Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum. Genet. 111(3), 299-302 (2002).
75. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N: Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med. 11(5), 593-600 (2003).
76. Dervieux T, Furst D, Lein DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50(9), 2766-2774 (2004).
77. Toffoli G, Russo A, Innocenti F et al.: Effect of methylenetetrahydrofolate reductase 677C>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer 103(3), 294-299 (2003).
78. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22(18), 3813-3825 (2004).
79. Heinrich MC, Corless CL, Demetri GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003).
80. Chen LL, Trent JC, Wu EF et al.: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 64(17), 5913-5919 (2004).
81. Hirota S, Nishida T, Isozaki K et al.: Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J. Pathol. 193(4), 505-510 (2001).
82. Tarn C, Merkel E, Canutescu AA et al.: Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin. Cancer Res. 11(10), 3668-3677 (2005).
83. Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11(12), 1513-1530 (2002).
84. Isla D, Sarries C, Rosell R et al.: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15(8), 1194-1203 (2004).
85. Ryu JS, Hong YC, Han HS et al.: Association between polymorphisms of ERCC1 and XPD and survival in nonsmall cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44(3), 311-316 (2004).
86. Zhou W, Gurubhagavatula S, Liu G et al.: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10(15), 4939-4943 (2004).
87. Rosell R, Taron M, Ariza A et al.: Molecular predictors of response to chemotherapy in lung cancer. Semin. Oncol. 31(Suppl. 1), 20-27 (2004).
88. Damia G, Silvestri S, Carrassa L et al.: Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer 92(4), 583-588 (2001).
89. Takebayashi Y, Pourquier P, Zimonjic DB et al.: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7(8), 961-966 (2001).
90. D'Incalci M, Colombo T, Ubezio P et al.: The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur. J. Cancer 39(13), 1920-1926 (2003).
91. Scotto KW: ET-743: more than an innovative mechanism of action. Anticancer Drugs 13(Suppl. 1), S3-S6 (2002).
92. Gurubhagavatula S, Liu G, Park S et al.: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22(13), 2594-2601 (2004).
93. Wang ZH, Miao XP, Tan W, Zhang XR, Xu BH, Lin DX: Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Ai. Zheng. 23(8), 865-868 (2004).
94. Borden EC, Amato DA, Rosenbaum C et al.: Randomized comparison of three adriamycin regimenns for metastatic soft tissue sarcomas. J. Clin. Oncol. 5(6), 840-850 (1987).
95. Palumbo R, Neumaier C, Cosso M et al.: Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur. J. Cancer 35(1), 66-72 (1999).
96. Pisters PW, Patel SR, Varma DG et al.: Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J. Clin. Oncol. 15(12), 3481-3487 (1997).
97. Hensley ML, Maki R, Venkatraman E et al.: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. 20(12), 2824-2831 (2002).
98. Talbot SM, Keohan ML, Hesdorffer M et al.: A Phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 98(9), 1942-1946 (2003).
99. Fata F, O'Reilly E, Ilson D et al.: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86(10), 2034-2037 (1999).
100. Kollmannsberger C, Brugger W, Hartmann JT et al.: Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 10(5), 453-456 (1999).
101. Bacci G, Picci P, Ferrari S et al.: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72(11), 3227-3238 (1993).
102. Chang AE, Kinsella T, Glatstein E et al.: Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J. Clin. Oncol. 6(9), 1491-1500 (1988).
103. Bramwell V, Rouesse J, Steward W et al.: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 12(6), 1137-1149 (1994).
104. Herson J, Sutow WW, Elder K et al.: Adjuvant chemotherapy in nonmetastatic osteosarcoma: a Southwest Oncology Group Study. Med. Pediatr. Oncol. 8(4), 343-352 (1980).